2024

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients With Chronic Thyroid Eye Disease (TEDD)

WALTHAM, Mass. , July 25, 2024–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on the discovery and advancement of high-quality potential medicines for serious and rare diseases, announced that enrollment For THRIVE -2, its Phase 3 clinical trial for VRDN-001 in patients with chronic PDD is complete.

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients With Chronic Thyroid Eye Disease (TEDD) Read More »